THE NOVEL HIV NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR RILPIVIRINE: A REVIEW OF INTERNATIONAL CLINICAL TRIALS
- Authors: KANESTRI V.G1
-
Affiliations:
- Federal Scientific-and-Methodic Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
- Issue: No 3 (2012)
- Pages: 54-61
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/275773
- ID: 275773
Cite item
Open Access
Access granted
Abstract
The review gives the results of Phases II and III international clinical trials of the efficacy and safety of antiretroviral therapy regimens incorporating the novel HIV nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine. The drug has the similar efficacy as the existing first-generation NNRTI agents, but a lower potential for toxicity. The important benefit of rilpivirine is that it has no negative effect on lipid metabolism, which is particularly important for patients having a higher cardiovarscular risk. The absence of cross-resistance presents a possibility of using this drug in patients with efavirenz and nevirapine resistance mutations. Rilpivinrine has been recently registered as first-line therapy in the USA, Europe, and Canada. At present, further investigations are called for the virological efficacy of the drug in patients with high baseline HIV RNA levels and in treatment-experienced patients.
Full Text
About the authors
V. G KANESTRI
Federal Scientific-and-Methodic Center for AIDS Prevention and Control, Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare
Email: kanestri@yandex.ru
Moscow
References
- Pozniak A.L., Morales-Ramirez J., Katabira E. et al. Efficacy and safety TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010; 24(1): 55-65.
- Cohen C., Molina J.M., Cahn P. et al. Оn Behalf of the ECHO and THRIVE Study Groups. Pooled week 48 efficacy and safety results from ECHO and THRIVE, two doubleblind, randomised phase III trials comparing TMC278 versus efavirenz in treatment-naive HIV-1-infected patients. 18th AIDS Conference. 18-23 July 2010, Vienna. Abstract THLBB206.
- Miller C.D., Crain J., Tran B. et al. Rilpivirine: a new addition to the anti-HIV-1 armamentarium. Drugs of today 2011; 47(1): 5-15.
- Goebel F., Yakovlev A., Pozniak A.L. et al. Short-term antiviral activity of TMC278—a novel NNRTI—in reatment-naive HIV-1-infected subjects. AIDS 2006; 20: 1721-1726.
- Sanford M. Rilpivirine. Drugs 2012; 73(4): 525-541.
- Rimsky L., Vingerhoets J., Van Eygen V. et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J. Acquir. Immune Defic. Syndr. 2012; 59: 39-46.
- Cohen C., Andrade-Villanueva J., Clotet B. et al. Rilpivirine versus efavirenz with two backgroundnucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adultsinfected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-237.
- Molina J.-M., Cahn P., Grinsztejn B. et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-246.
- Katlama C., Clotet B., Mills A. et al. Efficacy and safety etravirine at week 96 in treatmen- experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir. Ther. 2010; 15(7): 1045-1052.
- Cohen C.J., Molina J.-M., Cassetti I. et al. Hooled week 96 efficacy, resistance and safety results from the double-blind, randomized, phase III trials comparing rilpivirine (RPV) versus efavirenz in treatment-naïve, HIV-1-infected adults. 6th IAS, 2011. Abstract TULBPE032.
- Guillemont J., Pasquier E., Palandjian P. et al. Synthesis of novel dyarilpyrimidine analogues and thear antiviral activity aganst human immunodeficiency virus type 1. J. Med. Chem. 2005; 48(6): 2072-2079.
- De Bethune M.R., Andries K., Azijn H. et al. TMC278 a new potent NNRTI with an increased barrier to resistance and good pharmacokinetic profile. 12th Conference Retroviruses Opportunistic Infect. 22-25 Feb 2005, Boston. Poster 556.
- Crauwels H., Heeswijk R., McNeeley D. et al. Relative bioavailability of a concept pediatric formulations of TMC278, an investigational NNRTI. 18th AIDS Conference. 18-23 July 2010, Vienna. Abstract THPIO158.
- Arasteh K., Rieger A., Yeni P. et al. Short-term randomized proof-of of principal trial TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir. Ther. 2009; 14(5): 713-722.
- Corbett J.W. et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2000; 43: 2019-2030.
- Van Klooster J., Hoeben E., Borghys H. et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob. Agents Chemother. 2010; 54(5): 2042-2050.
- Verloes R., Van Klooster J., Baert L. TMC278 long acting - a parenteral nanosuspension formulanion that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. 17th AIDS Conference. 3-8 Aug 2008, Mexico City. Abstract TUPE0042.
Supplementary files
